← Back to Home

Making the Retina Light-Sensitive Again: Optogenetic Therapy Shows Signs of Visual Improvement in a Ten-Patient Trial

A gene injection combined with special glasses helped some patients with advanced retinitis pigmentosa detect light and perform object recognition tasks. However, this early trial has not established efficacy, nor has it restored normal vision or the ability to read.

By SURL BioNews

As the eye’s light-sensing cells gradually disappear, can surviving retinal nerve cells take over the task of sensing light? An early human trial published in The New England Journal of Medicine offers new clues for this treatment approach: after ten patients with advanced retinitis pigmentosa received optogenetic therapy, seven showed improved light sensitivity, and some were better able to perform simple visual tasks while wearing special glasses.

The phase 1/2 trial, called PIONEER, evaluated GS030, developed by GenSight Biologics. The study’s primary objective was to assess safety, while visual function tests were exploratory analyses. The results therefore support further research but are insufficient to establish that the treatment is effective. The University of Pittsburgh and UPMC also explicitly noted that patients did not regain normal vision or the ability to read.

Retinitis pigmentosa is a group of inherited diseases that cause the cells responsible for sensing light to progressively degenerate. GS030 attempts to bypass these nonfunctional cells: an intravitreal injection into one eye delivers the ChrimsonR gene to surviving retinal ganglion cells, enabling them to produce a light-sensitive protein. Camera-equipped glasses and a portable processor then convert images of the surroundings into light signals that can stimulate these cells, allowing the gene therapy and external device to work together.

Changes in light sensitivity were assessed using full-field stimulus threshold testing, which measures how faint a light patients can detect. Seven participants showed improvement, with six reaching the threshold the study used for a “clinically meaningful” increase. However, this threshold was not prespecified before the trial began, so the findings must be interpreted with caution. It also cannot be directly equated with patients being able to read or independently perform daily activities.

Behavioral tests provided another layer of evidence. According to a joint announcement from GenSight and the Quinze-Vingts National Eye Hospital in Paris, four of the eight participants who completed testing showed improvement while wearing the glasses in tasks such as detecting, locating, or touching objects, or judging line orientation. UPMC noted that these four participants showed consistent improvement across multiple tasks over follow-up periods ranging from months to years. Brainwave recordings in some participants also showed changes consistent with visual signals reaching the brain’s visual cortex, although these findings remain exploratory evidence.

The safety results also require a full assessment. The study recorded one severe, transient retinal artery occlusion. The joint announcement stated that the only ocular event classified as serious resolved within minutes after Iopidine eye drops were administered. Most ocular adverse events were mild or moderate, and no systemic adverse events were judged to be related to the study treatment or injection. However, a sample of ten patients remains insufficient to rule out rarer or long-term risks.

The significance of this trial lies in enabling cells that do not normally sense light to participate in visual processing, and in measuring some functional changes in human patients. Larger studies with prespecified efficacy criteria will be needed to clarify which patients may benefit, how long improvements may last, and whether gains on these tests can translate into practical benefits in daily life. GS030 has not yet received marketing authorization in any country.

References

  1. New England Journal of Medicine via PubMed
  2. UPMC / University of Pittsburgh
  3. GenSight Biologics and Hôpital national des 15-20